2015
DOI: 10.1089/jop.2014.0094
|View full text |Cite
|
Sign up to set email alerts
|

Intravitreal Triamcinolone Acetonide in the Treatment of Ophthalmic Inflammatory Diseases with Macular Edema: A Meta-Analysis Study

Abstract: Intravitreal injections of TA may offer certain advantages over the standard of care for ocular inflammatory diseases, especially in the early stage of follow-up. However, it is necessary to take into account risks and benefits of TA treatment for ocular inflammatory diseases due to possible ocular hypertension elicited, in general, by intravitreal injection of corticosteroids.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
5
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 48 publications
(47 reference statements)
0
5
0
Order By: Relevance
“…There is in general, a concern over a higher incidence of IOP elevation following intravitreal use of triamcinolone acetonide. 30 The implant is considered safer than other corticosteroids for ocular use. 21 Also, a retrospective comparative case series 31 found the dexamethasone implant superior to sub-tenon corticosteroids in the treatment of inflammatory cystoid macular edema, including CME, due to Irvine-Gass syndrome both in terms of efficacy and safety.…”
Section: Discussionmentioning
confidence: 99%
“…There is in general, a concern over a higher incidence of IOP elevation following intravitreal use of triamcinolone acetonide. 30 The implant is considered safer than other corticosteroids for ocular use. 21 Also, a retrospective comparative case series 31 found the dexamethasone implant superior to sub-tenon corticosteroids in the treatment of inflammatory cystoid macular edema, including CME, due to Irvine-Gass syndrome both in terms of efficacy and safety.…”
Section: Discussionmentioning
confidence: 99%
“…Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents (bevacizumab, ranibizumab, aflibercept) are the standard of care for treatment of diabetic macular edema (DME) ( Hatamnejad et al, 2024 ), but recently also brolucizumab and faricimab have been approved for DME treatment ( Montesel et al, 2021 ; Wong et al, 2023 ). In some cases, also intravitreal steroids, such as dexamethasone and triamcinolone acetonide are indicated to treat DME ( Bucolo et al, 2015 ; Bucolo et al, 2018 ). Besides these mentioned pharmacological treatments, several unmet medical needs affect diabetic retinopathy management: burden of care due to high cost and invasive intravitreal treatments, poor adherence, and 40%–50% of cases refractory to current approved pharmacological interventions ( Hatamnejad et al, 2024 ; Mandava et al, 2024 ).…”
Section: Introductionmentioning
confidence: 99%
“…Triamcinolone is a corticosteroid that is five times more potent than the natural compound cortisol, making it an extremely potent anti-inflammatory agent,9 and it is approved by the United States Food and Drug Administration for the management of chronic ocular inflammatory conditions, such as uveitis 10. Additionally, triamcinolone has been reported previously to prevent postoperative complications after pediatric lensectomy,11 making it an appropriate choice to investigate in this rabbit animal model.…”
Section: Introductionmentioning
confidence: 99%